pleased be first in CEO my IRIDEX. call joining thank us. and Thank you, participating afternoon Leigh. you to of as I'm all Good for
served role CEO As you year taking know, months before for I the a X ago. of on the many Board IRIDEX of
unique company's Strong with technology as I in the because and was long and ophthalmology. in attracted and industry reputation MicroPulse both glaucoma treatments the was to for IRIDEX innovator impressed I retina leader offerings around history initially a therapy.
confidence believe gaining market background and to leadership space. ability the to potential, the to adoption expand role. as In managing medical the raised particularly was in my the the the to succession, glaucoma to device in potential. Board we the began directly situation, significant considered CEO for companies applicable value be in hand as company's my for When my and been needed year, past its continue realize I penetration IRIDEX early was to consider company's confident provide I I've I in
focused to therapy, glaucoma keys adoption probe outcomes long-term First, I the sales deeper recurring patients company joining sales. future transitioning to executive driving our managing team mainline success. revenue from procedure the are areas tool drive I the for believe on a the of glaucoma and our physician include: team, Since to thereby activities in our shifting These MicroPulse disposable
product execution stabilize business. to clear is value Second, potential higher the reducing compelling. and company strategies our And cash on The third, burn. of our retina
are set making that path the achieving to these on However, to we're value. adjustments us necessary
demonstrated in to have and therapy is specialists meaningful to opportunity a and laser a tool Today, intraocular comprehensive transscleral our glaucoma, opportunity this biggest it's with early-stage repeatedly we been glaucoma more to ophthalmologists. pressures. company's The consistently MicroPulse from transition reduction adoption to mainstream in therapy, significant provide a
peer-reviewed the presented to have been To date, publications including attested procedures society and more than at XX XX strong safety. efficacy, durability that industry meetings, studies have
rest This those shipped of XX the million in of over the we shipped that are probes nearly developed sites; U.S. to probes in to a last XX,XXX diagnosed the market and user growth include we've which world. months U.S. XX in with is estimated that about success us between in build were patients XX-XX million XXX,XXX X.X Cumulatively, X,XXX opportunity gives this split confidence the penetration glaucoma initial can countries, a of the
stage with are to segment of largest patients patients being that disease and the direct warrants more U.S. surgeries. treated glaucoma a advanced eye that worldwide drop than of have therapies and moving Though multiple early and X.X therapy, million more
Our therapy the attractive segment directly significantly market, alternative. offering transscleral a laser large addresses this of
confidence in adoption retreatment repeatable and gaining to benign education mid-stage therapy, a All leading aspects us and the now. they must offer appealing an we Our pressure. will noninvasive ahead longer making glaucoma first-hand are direct leading therapies them increase experience broader we select to In choice. believe our us accomplish eventually the reduction, surgeries action goal segment, use, support. to choices and we is of durable physicians ease safety greater We support the where profile fail, and and and as IOP adoption additional to IOP are shift needed patients to later to intraocular glaucoma We achieve drops share control capture of control. potential of make adequate this no via for of physician clinical believe this we eye focus order
therapy For procedures. patient's safely period example, shown has a transscleral IOP to MicroPulse over X X-year used study laser manage repeat using
hands teams physician. of in requires through treatment the target learning work broader techniques and time believe held week, team MicroPulse with probes attention we a our right to therapy, use and range we patients, embracing clinical and treatment of to meeting, the new the lead we outcomes U.S. where curves will that implemented of in their outcomes appropriate our through truly which the phases supports process patients. sales on common in each the customers Last of validating benefits in moving customers their MPX spend that a hands understanding of focused sales more validate a and This
laser real-world broader usage that therapy studies is higher hands-on adoption that effective, all to validation MicroPulse demonstrating the customer and combining rates. with believe and experience, safe, durable lead We we'll and
great done job base installed market has a worldwide IRIDEX a building and awareness.
lower the of adoption customers systems new use, and the to we the in increase placements concentrate and near time to U.S. see As our spent sales we efforts term, more on clinical in rate a with expect
Many the Cyclo discontinued with a sales GX priced of seeing placements result, program, program the system a probes. are bundled the LAP system a under probe And We the our the a an LAP units. volume second reorders and in program package shipments GX in we reduction with system associated were contribute per as with sold U.S. call of and revenues This quarter, the system attractively rather we XX in decline ASP placements. impact over and than systems. will margins those initial initial gross mitigating from through improve recognized shift sold, will somewhat time, package realize probe to financial
new will be placed those place users. potential over systems of with systems and significant confident higher I'm However, time, continue we'll to number volume
despite international. our elimination of achieved improvement results XX% and of This shipments of balanced the the LAP program. in record to was approximately the in quarter Turning number shipments second U.S. probes, increase, quarter broad-based a glaucoma. this XX,XXX year-over-year in We with the probe
Importantly, in we the we on QX, be extending of markets. and increasing probe focused both highest is forward. number saw the going reorders the trend in international will U.S. This and
quarter, to Cyclo our we of and shipped Due in adoption QX year. the probe in discontinuation last systems on XXX the LAP XX and reduction from a the focus shift GX program reorders, towards
reducing shipments XXX range are to our to this from XXX of XXX shift, to we a XXXX XXX. for GX Given Cyclo guidance system
of in of that activities a our clinical value part proposition As we're specifically focus support adoption, therapy. our investing on the driving
first that observed participants. nearly April, In did was webinar we by our XXX glaucoma
one glaucoma second where also Our of Cycle with experiences GX his was technology. and shared in first users about attended, well our talked treating the one cases July and clinical research
encourage regional to activities of types these well. as peer-to-peer expanding be We'll and education endorsement
out world the Latin Association busiest-ever multiple seminars at XX America, we Highlights and the in ophthalmic Finally, Pan-American in meetings. door. the successful a Cancún first-ever X our and had symposium symposium booth symposiums the around our with at speakers attendees and XXX exhibitions, X include Mexico, speakers, Germany with event Ophthalmology in society and attendees, line
with allowing the last a we objective probe cases of completed on that user technique the starting the glaucoma consistency The probe base. and limited intuitive, ergonomic with PX is development of The MicroPulse gain enhanced begun simplifying clinical greater is and our experience, item have updated to use. more news
are promote in received We'll very start and in shipments Early rollout confidence begin being later performing this high-quality procedures. should is well in indications that QX. broader and increased QX commercialized probe
to of approximately decrease In second XXXX, of $X.X from for were products a quarter total year-over-year retina retina Turning our representing segment. million, the our about X% revenues revenue, business. that XX% of
line line of EndoProbes As for we lasers retina surgery a other surgical disposable reminder, have diseases, of and product X and a for photocoagulation retinal the and lines, retinal macular diabetic a interoperative and advanced retinopathy. edema detachment for used diabetic medical retina treatment
retina between surgical. is equal split and Our about medical business
trust and we With retina continue experience been probes, history. a strong medical the over installed our historical with base, of while customers of developed Yet systems stable XX-year has laser the therapy business in retina a know disposable brand challenges retina. and IRIDEX laser a larger mix company. has fairly to surgical reputation its
looking margin gross the are that improvement. to better to stability realities and in position ways We of address market products the to our contribute at revenue order
a market. of been compete position more previously, price-sensitive plan laser and has discussed better involves As reduced in that to mature systems cost to our long-term us updated introduction the with manufacture will
that in line glaucoma new First both of the will retina introduction applicable be XXX-nanometer system treatments. is a in and
development breakeven launch and because margins, These they to burn, cash market planned new important cash allow in dates. reach our working and are sooner. lower-cost up programs, firm and evaluating to I'm our flow us milestones raise We're our systems reduce us help schedule
our XXXX, shipments. guidance has probe for we reaffirm been our to growth therapy expectation solid, Lastly, glaucoma MPX year of XX,XXX and turning probes XX,XXX full to of
sales from mitigating XXX adoption improve range to do units. our ASPs our we to XXX. guidance Cyclo uses expect However, GX half reducing the to fewer focus as of our impact higher shipments further total procedure a rates, systems to to system We we are XXXX, in of the probe shift XXX for XXX second of drive and
to from revenue a $XX guidance million are This $XX contribute of that X factors range also million were revising in expected to to $XX attributable is We our to to million largely $XX million. revenue. changes XXXX to
business, forecasted our LIO retina medical are not delivery business recall. device of we instead the First, on has That last voluntary reintroduction seeing after in our the trend. following year's stayed increase
I probe utilization, we contribution expect Second, shift the drive focus glaucoma to sales. system lower in somewhat a GX Cyclo from as described of revenue result
platform GX thus, regulatory and third, is our not XXXX revenue. of pushed the approval China quarters our will anticipated several contribute back to And
ophthalmic manufacturers and Our likely U.S.-China in approvals slowdown FDA trade carries several partner U.S. due China from a observed board, China across the lines distributor in tensions. of has products to
that highly In of growth. motivating attracted was for the is our opportunity despite impacting IRIDEX some me to I near-term value headwinds unchanged summary, and
while adoption refine to and reducing to drive I improve innovations my and burn focus maintaining on As operational support our on execution efficiencies. Board strategies, is focus programs leadership through continue cash team to customers work that with our our and
I'd to Romeo? the like more Romeo second call to results quarter Now turn our detail. XXXX over financial in discuss to
